← Eichor
Study identifier: NCT06333899 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Condition: High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Anaplastic Astrocytoma  ·  Sponsor: Nationwide Children's Hospital

PhaseEARLY_Phase 1
Planned participants15
Who can joinAll sexes, 1 Year to 21 Years
Healthy volunteersYes

About this study

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Kelsey H Troyer, PhD  ·  16147223284  ·  kelsey.troyer@nationwidechildrens.org

Always discuss trial participation with your own doctor first.

Locations (18)

Children's Hospital ColoradoAurora, Colorado, United StatesNot Yet Recruiting
Children's National Medical CenterWashington D.C., District of Columbia, United StatesNot Yet Recruiting
Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois, United StatesNot Yet Recruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesNot Yet Recruiting
Duke University Health SystemDurham, North Carolina, United StatesNot Yet Recruiting
Cincinnati Children's Hospital Medical CenterCincinnati, Ohio, United StatesRecruiting
Nationwide Children's HospitalColumbus, Ohio, United StatesRecruiting
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania, United StatesNot Yet Recruiting
Texas Children's HospitalHouston, Texas, United StatesNot Yet Recruiting
Seattle Children's HospitalSeattle, Washington, United StatesNot Yet Recruiting
Sydney Children's HospitalRandwick, New South Wales, AustraliaNot Yet Recruiting
Queensland Children's HospitalSouth Brisbane, Queensland, AustraliaNot Yet Recruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06333899